The safety of application of laxatives


如何引用文章

全文:

详细

The constipation occurs in 16-27% of population and only one third of patients seek medical care. The laxatives are traditionally applied for stool regulation. At the same time, 4.18% of patients make excessive use of these pharmaceuticals. The article characterizes the main groups of laxatives and presents the results of meta-analysis of effectiveness of preparations including description of unfavorable effects with formation of laxative disease. The original clinical case of female patient with severe form of laxative disease is presented. The treatment of this complication is described. It is emphasize that key role is played by withdrawal of pharmaceutical caused laxative disease and correction of electrolyte disorders and recovery of functioning of stomach. The good results of treatment is ensured by lactulose due to safety, good tolerance and additional effects, in particular normalization of composition of gut organisms.

作者简介

Elena Luzina

The Chita state medical academy

Email: el.luz@list.ru
MD, PhD, assistant professor of Chair of Therapy for post-degree education 672090 Chita, Russia

参考

  1. Chang J.Y., Locke G.R. III, McNally M.A., Halder S.L., Schleck C.D., Zinsmeister A.R. et al. Impact of functional gastrointestinal disorders on survival in the community. Am. J. Gastroenterol. 2010; 105: 822-32.
  2. Higgins P., Johanson J.F. Epidemiology of constipation in North America: A systematic review. Am. J. Gastroenterol. 2004; 99: 750-9.
  3. Tack J., Muller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin. Gastroenterol. Hepatol. 2009; 7 (5): 502-8.
  4. Stewart W.F., Liberman J.N., Sandler R.S., Woods M.S., Stemhagen A., Chee E. et al. Epidemiology of constipation (EPOC) study in the United States: Relation of clinical subtypes to sociodemographic features. Am. J. Gastroenterol. 1999; 94: 3530-40.
  5. Агафонова Н.А., Яковенко Э.П. Синдром хронического запора у пациентов, злоупотребляющих слабительными раздражающего действия. Русский медицинский журнал. 2010; 28: 1735-41.
  6. Robson K.M., Kiely D.K., Lembo T. Development of constipation in nursing home residents. Dis. Colon Rectum. 2000; 43: 940-3.
  7. Pare P., Ferrazzi S., Thompson W.G., Irvine E.J., Rance L. An epidemiological survey of constipation in Canada: Definitions, rates, demographics, and predictors of health care seeking. Am. J. Gastroenterol. 2001; 96: 3130-7.
  8. Neims D.M., McNeill J., Giles T.R., Todd F. Incidence of laxative abuse in community and bulimic populations: a descriptive review. Int. J. Eat. Disord. 1995; 17: 211-28.
  9. Roerig J.L., Steffen K.J., Mitchell J.E., Zunker C. Laxative abuse: epidemiology, diagnosis and management. Drugs. 2010; 70 (12): 1487-503.
  10. Bruckert E., Rosenbaum D. Lowering LDL-cholesterol through diet: potential role in the statin era. Curr. Opin. Lipidol. 2011; 22: 43-8.
  11. Pare P. The approach to diagnosis and treatment of chronic constipation: Suggestions for a general practitioner. Can. J. Gastroenterol. 2011; (Suppl. B): 36B-40B.
  12. Полуэктова Е.А., Кучумова С.Ю., Шептулин А.А., Ивашкин В.Т. Лечение синдрома раздраженного кишечника с позиций современных представлений о патогенезе заболевания. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013; 1: 57-65.
  13. Парфенов А.И. Три варианта патогенеза и терапии хронического запора. Экспериментальная и клиническая гастроэнтерология. 2012; 3: 7-19.
  14. Liu L.W.C. Chronic constipation: current treatment options. Can. J. Gastroenterol. 2011; 25 (Suppl. B): 22B-8B.
  15. Ford A.C., Suares N.C. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011; 60 (2): 209-18.
  16. Сhen X., Zhai X., Kang Z., Sun X. Lactulose: an effective preventive and therapeutic option for ischemic stroke by production of hydrogen. Med. Gas Res. 2012; 2: 3.
  17. Ерофеев Н.П., Радченко В.Г., Селиверстов П.В. Клиническая физиология толстой кишки. Механизмы действия короткоцепочечных жирных кислот в норме и при патологии. СПб.: Форте Принт; 2012.
  18. Panesar P.S., Kumari S. Lactulose: production, purification and potential applications. Biotechnol. Adv. 2011; 29 (6): 940-8.
  19. Pare P., Bridges R., Champion M.C., Ganguli S.C., Gray J.R., Irvine E.J. et al. Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Can. J. Gastroenterol. 2007; 21(Suppl. B): 3B-22B.
  20. Hallmann F. Toxicity of commonly used laxatives. Med. Sci. Monit. 2000; 6(3): 618-28.
  21. Mueller-Lissner S., Kamm M.A., Wald A., Hinkel U., Koehler U., Richter E. et al. Multicenter 4-week double-blind randomized placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am. J. Gastroenterol. 2010; 105: 897-903.
  22. Белоусова Е.А., Никулина И.В. Принципы выбора слабительных средств у разных категорий больных запором. Фарматека. 2009; 2: 48-53.
  23. Creytens G. Le Lactulose dans le traitement de la constipation chronique et 1’abus des laxatifs. Аrs Med. 1980; 35: 737-57.
  24. Boisson J. Trial with duphalac (lactulose) for the withdrawal of irritant laxatives. Results of a double-blind, multicentre clinical trial involving patients whose irritant laxatives were withdrawn overmight. Le Concours Med. 1991; 1-12.

版权所有 © Eco-Vector, 2014


 


##common.cookie##